Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1991-10-24
|
pubmed:abstractText |
In this study we analyzed the induction of NK and LAK cell functions by TNF alpha, alone or combined with IL-2, in 4 days in vitro culture of PBMC from patients treated with alpha IFN + IL-2. Although the MN cell recovery after 4 days culture was very similar with TNF alpha alone or with IL-2 alone, TNF alpha did not maintain nor induce LAK or NK activities of in vivo preactivated PBMC. When compared to preculture values, TNF alpha alone induced a preferential outgrowth of CD4+ T cells together with a decrease of CD8+ T cells, NK cells and IL-2R (p55)-expressing cells. The combination of TNF alpha (100 ng) and high dose IL-2 (9,000 IUg/ml) did not improve the MN cell recovery after 4 days culture; but increased IL-2-induced NK activities in PBMC from 6/7 patients, and IL-2-induced LAK activities in 4/7 patients. However, these variations were not significant. The combination of TNF alpha and lower doses of IL-2, ranging from 150 IU/ml to 30 IU/ml, did not modify MN cell recovery in culture nor IL-2-induced NK and LAK cell activities. When compared to paired samples cultured with IL-2 alone, the combination of TNF alpha with all doses of IL-2 did not modify the distribution of T and NK cells, but increased the expression of CD8 on NK cells. Furthermore, the combination of TNF alpha and IL-2 increased the expression of IL-2R (p55) on PBMC but the expression of this receptor was restricted to CD4+ T cells and did not appear on NK cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1148-5493
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
221-7
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2104243-Antigens, CD,
pubmed-meshheading:2104243-Carcinoma, Renal Cell,
pubmed-meshheading:2104243-Cell Division,
pubmed-meshheading:2104243-Cells, Cultured,
pubmed-meshheading:2104243-Humans,
pubmed-meshheading:2104243-Immunity, Cellular,
pubmed-meshheading:2104243-Immunologic Factors,
pubmed-meshheading:2104243-Interleukin-2,
pubmed-meshheading:2104243-Kidney Neoplasms,
pubmed-meshheading:2104243-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:2104243-Killer Cells, Natural,
pubmed-meshheading:2104243-Leukocytes, Mononuclear,
pubmed-meshheading:2104243-Lymphocyte Activation,
pubmed-meshheading:2104243-Recombinant Proteins,
pubmed-meshheading:2104243-T-Lymphocyte Subsets,
pubmed-meshheading:2104243-Tumor Necrosis Factor-alpha
|
pubmed:articleTitle |
TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
|
pubmed:affiliation |
Centre Léon Bérard, Lyon, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|